Abstract
We had demonstrated that intravenous administration of bone marrow derived mononuclear cells or hematopoietic stem cells improves functional recovery through enhanced angiogenesis in experimental stroke model. Based on these observations, we started phase 1/2a clinical trial of cell-based therapy for patients with cardiogenic cerebral embolism (ClinicalTrials.gov ID: NCT01028794). The results of clinical trial indicated that autologous bone marrow cell transplantation at day 7–10 after onset of stroke is feasible and safe in patients with severe stroke, and patients with cell therapy had better neurological outcomes, compared with historical control group. Our results encouraged us next randomized clinical trials to confirm the effect of cell therapy for patients after stroke.
